At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 142 enrolled
Drug / intervention
ALRN-6924drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 Alone or in Combination in Patients With Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein
In Brief
A Phase 2 clinical trial evaluating ALRN-6924 for Solid Tumor and 2 related conditions. Completed, enrolled 142 participants across 13 sites.
Detailed Summary
This study evaluates the anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with WT TP53.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Lymphoma, Peripheral T-Cell Lymphoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartOct 2014
First PostedOct 2014
Primary CompletionMar 2020
Study CompletionApr 2020
TodayJul 2026
First PostedOct 15, 2014
Enrollment StartOct 1, 2014
Primary CompletionMar 1, 2020
Study CompletionApr 1, 2020
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 11.7 years ago
Interventions
ALRN-6924drug
ALRN-6924 will be administered as an IV infusion